Abstract:Objective: To explore the efficacy and safety of the third-line or above therapy of inetetamab combined with pyrotinib in patients with advanced Her2 positive breast cancer. Methods: Clinical data of 10 patients with advanced Her2 positive breast cancer treated with inetetamab combined with pyrotinib after the failure of multiline therapy were collected to analyze the short-term efficacy, adverse reactions, and the survival. Results: The follow-up went until April 1, 2021. The objective response rate was 90% (9/10) , and the median progression-free survival time was 5.87 months. The efficacy of 10 patients with advanced Her2 positive breast cancer was as follows: 0 case of CR; 9 cases of PR, of which 1 PR patient suffered interruption for economic reasons and was remained stable. The progression-free survival time of the other PR patient was 5 months, and then the patient died of the progress of pulmonary metastasis, pleural effusion, and atelectasis, despite emergency rescue efforts. After 9 courses of treatment, 1 PR patient changed the therapy due to "the progression of pulmonary metastasis" , and the condition was still under evaluation. The remaining 6 patients were still in follow-up. One SD patient was treated with advanced fifth-line therapy, and the progression-free survival of the SD patient was 1.5 months. The SD patient died of the progression of pulmonary metastasis, despite emergency rescue efforts. The main adverse reactions during treatment were fatigue, stomach distension, and diarrhea. Of these, 70% (7/10) of patients had grade 2-3 fatigue and stomach distention, and 90% (9/10) of patients had grade 1-2 diarrhea. Most patients had mild bone marrow suppression in the combination with chemotherapy. Conclusion: The treatment regimen of inetetamab combined with pyrotinib (China double target) in patients with advanced Her2 positive breast cancer after the failure of multi-line therapy has significant short-term efficacy and good safety, which is worthy of further large sample follow-up observation and comparative study.
